Backgrounds: A p16 protein is known to be overexpressed in human papillomavirus-positive head and neck squamous cell carcinoma specimens. p53 is a tumor suppressor protein detectable by immunohistochemistry in carcinogen-associated head and neck squamous cell carcinoma as a result of gene mutations. The purpose of this study is to investigate the prognostic impact of p16 and p53 expression in oropharyngeal squamous cell carcinomas. Methods: We retrospectively examined the relationship between prognosis, and p16 and p53 expression levels of oropharyngeal squamous cell carcinoma specimens in 53 patients using immunohistochemistry. Results: Overall, 55% of patients were p16 positive and 45% p16 negative, while 28% were p53 positive and 72% p53 negative. The p16 status showed an inverse relationship with the p53 status. A survival analysis by p16 status, p53 status, Union for International Cancer Control stage and main treatment modality demonstrated that only p16 status was related to better prognosis in terms of overall survival and disease-specific survival (3-year overall survival, 87 vs. 62%, P ¼ 0.02; 3-year disease-specific survival, 90 vs. 62%, P ¼ 0.02). To evaluate the practical prognostic factors in oropharyngeal squamous cell carcinoma patients, we classified patients as either p16-positive or p53-negative oropharyngeal squamous cell carcinomas, representing human papillomavirus-related oropharyngeal squamous cell carcinoma with wildtype p53 or the remaining patients with p16-negative or p53-positive OPSCCs, respectively. The former group showed survival advantages in terms of overall survival and disease-specific survival by log-tank test compared with the latter group (3-year overall survival, 96 vs. 58%, P ¼ 0.005; 3-year disease-specific survival, 96 vs. 63%, P ¼ 0.02). Conclusions: A group of patients who were p16 positive/p53 negative had better prognoses in terms of overall survival and disease-specific survival than that who were p16-positive alone.
INTRODUCTION
Several previous meta-analyses or large cohort studies have confirmed an improved response to treatment and better survival of patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), compared with HPV-negative patients (1 -3) . The 2012 National Comprehensive Cancer Network guidelines recommended that pre-treatment work-up for OPSCC should include immunohistochemical staining (IHC) for p16, as well as HPV testing by in situ hybridization, because of the good availability of the technique (4) . A p16 protein, which is expressed downstream of retinoblastoma (Rb) inactivation by E7, an oncoprotein generated by HPV, is known to be overexpressed in HPV-positive head and neck squamous cell carcinoma (HNSCC) specimens and as a surrogate marker of HPV (5 -7) . A p16 IHC status may be useful for classifying patients with OPSCC and for influencing treatment strategies in accordance with this classification.
However, several studies have demonstrated no survival advantage in patients with HPV-positive HNSCC (8 -11) , and some have indicated a negative correlation between HPV positivity and survival (12, 13) . The apparent discrepancies between these reports suggest that the survival advantage of HPV-positive tumors may vary according to location or circumstances. It is possible that the influence of HPV infection on survival of OPSCC patients differs in relation to exposure to other carcinogenic factors, such as smoking or alcohol. Ang et al. (1) . reported the results of the RTOG 0129 study, which helped to clarify the effects of smoking and HPV status on survival, and suggested that changes at the molecular level, as a result of repeated carcinogen exposure may negate the molecular changes associated with HPV positivity. They also proposed that patients should be classified into risk-of-death categories according to HPV status and number of tobaccopack years (1) .
In addition to using p16 IHC as a marker of HPV status, this study also focused on p53, which is commonly mutated in tumors in smokers (14, 15) . However, the missenses of p53 gene in the tumor of human squamous cell carcinoma exist in various sites (16) and so, the techniques such as DNA PCR and DNA sequence are required, which are not commonly available. In this study, we analyzed the p53 protein by IHC instead of analyzing p53 gene mutations, because of the ready availability of the technique (14) . We retrospectively analyzed OPSCC specimens using IHC for p16 and p53 and classified the patients on the basis of the results. We also clarified the morphological characteristics of the tumors, tumor proliferation potency, and patient data according to this classification, and investigated the effects of this classification on survival. The results of this study may help to stratify patients with OPSCCs in terms of their survival and also help to modify their treatment according to this classification.
PATIENTS AND METHODS

PATIENT DATA
Archival, formalin-fixed paraffin-embedded biopsied specimens from patients with OPSCCs who had been diagnosed in the Department of Otolaryngology and Head and Neck Surgery in Kobe City Medical Center General Hospital between 2004 and 2012 were re-examined by histology and immunohistochemistry. Of a total of 55 patients, 54 were biopsied from the primary site and 1 was biopsied from a metastatic cervical lymph node. Clinical information collected by chart review and follow-up included age at diagnosis, gender, clinical stage (Union for International Cancer Control version 7: UICC), treatment and survival. Two patients who received no treatment because of poor general condition or refusal of all medical interventions were excluded from this study. In total, the study consisted of 42 men and 11 women, aged 36 -77 years (median, 64 years). The distribution of tumor subsites was 33 in tonsil, 11 at the base of the tongue, 5 in soft palate and 4 in the posterior wall. The characteristics of 53 patients are shown in Table 1 .
TREATMENT MODALITY
As shown in several known guidelines, there are multiple choices in treating with OPSCC and patients' requests should be respected in choosing a definitive therapy.
Based on this, the treatment modalities in our institute were as follows:
For cases with small tonsillar carcinoma initially diagnosed as origin unknown cervical squamous cell carcinoma (cT0 N þ cases), tonsillectomies for biopsy and neck dissections (NDs) were followed by radiation with concurrent chemoradiotherapy (CRT) or induction chemotherapy (IC). For cases with Stage I or II, radiotherapy (RT) with or without concurrent chemotherapy was essentially recommended. When the volume of the primary tumor was large, IC preceded the definitive therapy and in case the response of IC was poor, surgery was recommended. Otherwise, RT or CRT was chosen for main treatment modality. Only a surgery can be performed when the primary tumor was The principles of the surgery were transoral primary resection plus incontinuous NDs for T1 -T2 cases and enbloc dissection of the primary site and neck lymph nodes followed by reconstruction for T3 -T4 cases. A postoperative RT (2Gy/fr/day, total 50 -60Gy) was planned when the primary site was margin positive or close to margin or when over three metastatic lymph nodes were pathologically detected or exracaspular invasions were seen in lymph node metastasis. In case RT or CRT (2Gy/fr/day, total 50 -72Gy) was chosen for definitive therapy, a post-therapeutic ND was planned when the residual tumor in lymph nodes were detected under the survey in 3 months. Due to older age or poor general condition, such as liver dysfunction, renal dysfunction or myocardiac infarction, we occasionally made a treatment plan without chemotherapy.
Treatment modalities in this study are shown in Table 2 . Platinum-fluorouracil (PF) therapy was the first choice for IC if the renal and the liver function was good enough. All of chemotherapeutic agents used in this study are listed in Table 3 .
HISTOLOGY AND IHC
Mouse monoclonal antibodies against Ki67 ( prediluted, Invitrogen Carlsbad, CA, USA), p53 ( prediluted, Dako, Glostrup, Denmark) and rabbit monoclonal antibody against p16/INK4a (1:500 dilution, Eptomics, CA, USA) were used as primary antibodies. Briefly, 4-mm serial sections were deparaffinized, then IHC was performed using the labeled streptavidin -biotin method and an automated staining system (Ventana BenchMark, Ventana Medical Systems, Inc., Tucson, AZ, USA). Positive immunoreactions were visualized using 3,3
0 -diaminobenzidine as a chromogenic substrate. Serial sections were stained with hematoxylin -eosin. IHC analysis and histological classification were conducted by two pathologists (Y.U. and Y.I.), who were blinded to the clinical information. Histologically, lesions were divided into either 'keratinizing' or 'non-keratinizing' according to the World Health Organization classification of tumors (17) . IHC scores were estimated in five randomly selected areas at Â400 magnification and then averaged. Briefly, nuclear p53-positive cells and strong nuclear and cytoplasmic p16-expressing carcinoma cells were counted. The percentage of positive cells was then estimated by dividing the number of p53-or p16-positive cells by the total number of carcinoma cells in the field. The cut-off value for the percentage of p16-positive cells was previously determined to be 50% in our institute, based on another study of 24 OPSCC patients who had 
234
P16 and p53 expression in oropharyngeal carcinomas undergone p16 IHC and HPV DNA analysis. In this study, the sensitivity and the specificity of p16 IHC were 100 and 75%, respectively, when the result of HPV-PCR was set at a standard (18) , which is almost identical to the past report (19) . On the other hand, a p53 antibody we used was DO7 clone which recognized N-terminal 1 -45 amino acids of p53 of human origin. The sensitivity for the missense of exon 5 through 9 of p53, where most of known abnormalities concentrate, was reported to be 75% (20) . The cut-off value for the percentage of p53-positive cells was also set at 50% following the previous report (21) . A positive Ki67 nuclear reaction was evaluated as MIB-1 index, which was the ratio of Ki67-positive nuclei to the total number of carcinoma cells (1000 cells).
In treating with human specimens, this study was approved by the Institutional review board of Kobe City Medical Center General Hospital, Japan.
STATISTICAL ANALYSIS
Clinical covariates were dichotomized for statistical evaluation: gender (male vs. female), the history of smoking (10 pack Comparisons of quantitative data, such as age and MIB-1 index, between the two groups were estimated by MannWhitney U tests. The overall survival (OS) and diseasespecific survival (DSS) were estimated by the Kaplan -Meier method and the differences between groups were assessed using the log-rank test. Cox multivariate regression analysis with forced entry was used to examine the significance of IHC profiling of OPSCC when other clinical prognostic factors (patient's age, UICC stage and main treatment modality) were included. Excel Tokei 2010 Software for Windows (SSRI, Tokyo, Japan) was used for statistical analysis and a P value of ,0.05 was considered to be significant.
RESULTS
CLINICAL FEATURES AND PATHOLOGICAL CHARACTERISTICS ACCORDING TO P16 AND P53 STATUSES
Among the 53 cases of OPSCC, 55% were p16 positive (29/ 53) and 45% were p16 negative (24/53), while 28% were p53 positive (15/53) and 72% were p53 negative (38/53). Table 4 shows the associations between p16 and p53 statuses and clinical features, pathological characteristic and potential risk factors for OPSCC. The patients with p16-positive OPSCCs were significantly younger than those with p16 negative. Smoking history was strongly related to p53 positivity. Morphology and tumor subsite were significantly related to the p16 status, but not to the p53 status. P16 positivity was associated with a significantly higher proportion of non-keratinizing morphology and tonsil subtype. There was no association between MIB-1 index and positivity for either p16 or p53. The p16 status showed an inverse relationship with the p53 status, but there were some double-positive (3 cases) and double-negative cases (12 cases). The UICC stage showed a higher tendency in p16-positive cases than p16 negative (P ¼ 0.051), which may give a disadvantageous bias in survival to p16-positive cases. The main treatment modality or the use of IC was not associated with p16 or p53 status.
SURVIVAL
The median time to death or last follow-up was 3.4 years (range 0.1 -7.8 years). There were 12 deaths in the OS and 9 in the DSS. Table 5 shows the 3-year survival rates based on biomarkers, morphology, UICC stage, main treatment modality and the use of IC. Patients with p16-positive OPSCC had significantly better OS and DSS. The 3-year OS rates in p16-positive and -negative patients were 87 and 62%, respectively, and the 3-year DSS rates were 90 and 62%, respectively (Fig. 1) . Patients with earlier UICC stage (Stages I -III) had better survival than those with Stage IV disease in terms of both OS and DSS, although the differences were not significant.
The survival distinctions were more apparent in the combined analysis of p16 and p53 statuses. Using p16-positive and p53-negative patients as a reference, the patients with p16-negative and p53-positive, double-negative and doublepositive IHC results had poorer prognoses in terms of OS (Fig. 2) . Double-negative patients also had a significantly poorer prognosis than p16-positive and p53-negative patients in terms of DSS.
PRACTICAL DICHOTOMIZATION BY IHC PROFILE
To evaluate the practical prognostic factors in OPSCC patients, we divided the patients into two groups: p16-positive and p53-negative OPSCCs, representing HPV-related OPSCCs with wild-type p53 and the remaining patients with p16-negative or p53-positive OPSCCs. Table 6 shows the associations between these two groups based on IHC profile and clinical features, pathological characteristics and potential risk factors. p16-positive and p53-negative patients were significantly younger, had non-keratinizing OPSCCs and had tonsillar lesions. The UICC stage, main treatment modality and the use of IC were similar in both groups. Differences in survival curves were apparent for both OS and DSS (Fig. 3) . p16-positive and p53-negative patients had a survival advantage over the other group (3-year OS, 96 vs. 58%, P ¼ 0.005; 3-year DSS, 96 vs.63%, P ¼ 0.02). Table 7 shows the adjusted hazard ratios (HRs) for OS and DSS in OPSCC patients associated with this practical grouping based on p16 and p53 IHC combination, UICC stage and main treatment modality. Multivariate analysis demonstrated that staging and the dichotomization according to IHC profile were independently associated with both OS and DSS.
However, p16 and p53 IHC combination showed higher HRs than staging both in OS and DSS. The patients with p16-negative or p53-positive OPSCCs had an HR of 20.8 (95% confidence interval (CI), 2.47 -174.2) for OS and 12.6 (95% CI, 1.48 -107.2) for DSS.
DISCUSSION
HPV infection is causally related to the development of HNSCC, independent of tobacco and alcohol use (22, 23) .
HPV DNA is commonly found in the oropharynx and is most commonly high-risk type 16. HPV infection, especially highrisk type, has been demonstrated to play a role in the molecular pathways of carcinogenesis through its viral oncoproteins, E6 and E7. E6 binds to p53 and marks it for degradation via a proteasome-dependent pathway (24) , while E7 binds and inactivates the Rb gene family of tumor suppressor proteins, leading to upregulation of p16 by loss of negative feedback control (25) . p16 and p53 are tumor suppressor genes and key targets in the loss of cell cycle control (26) . The p16 gene is naturally inactivated in HPV-negative HNSCC, but is 
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P16 and p53 expression in oropharyngeal carcinomas frequently, though not exclusively, found in HPV-associated HNSCC, where p16 expression serves as a surrogate biomarker of oncogenic HPV infection in predicting HPV-related tumors (7, 27) . In the present study, p16-positive OPSCC demonstrated some characteristics of HPV-associated OPSCC, including younger age, non-keratinizing cellular morphology and tonsillar lesions (7, 28) . MIB-1 index, also known as Ki67 index, is an important marker of cell proliferation. El-Mofty and Lu (28) reported an increased MIB-1 index in non-keratinizing OPSCC, which was highly related to HPV-positive OPSCC. In our series, the median MIB-1 indexes of p16-positive and p16-negative OPSCCs were similar (58 vs. 52), indicating no significant differences in proliferative ability between these two groups. Previous survival analyses revealed that patients with HPV-associated OPSCC showed significant improvements in survival when treated by surgery (29, 30) or RT (2,31,32) . Patients with p16-positive OPSCCs in the current series had significantly better prognoses in both OS and DSS. Interestingly, several studies found that not all tumors that were p16 positive by IHC were also HPV positive, and that the risk of death in patients with head and neck tumors that stained positive for p16 was reduced more than expected based on HPV positivity alone (1) . This suggests that p16 may be a more useful predictive biomarker of improved survival than HPV status, especially in light of the greater availability of the test compared with HPV status, which requires more cumbersome laboratory tests to detect viral DNA.
p53 mutations are frequently observed in HNSCC in smokers, are thought to play a major role in carcinogenesis of HNSCC and have been identified in carcinogen-associated HNSCCs. However, p53 mutation is an uncommon event in HPV-associated HNSCC (33, 34) suggesting that p53 mutations are not a prerequisite for HPV-induced tumor development. p53 missense mutation has been reported to increase protein stability, which can be easily detected by IHC (35, 36) . In this study, p53 IHC status showed a strong inverse correlation with p16 IHC status. Smoking condition also showed a strong correlation with p53 IHC status and an inverse correlation with the p16 status. However, there were 61% smokers with p53-negative OPSCC. This may be due to various susceptibilities of p53 genes to tobacco or simply due to inadequate sensitivity of p53 IHC for detecting p53 mutations (20) . The questionnaires only acquired self-reported information on smoking habits, which may not have reflected actual genomic changes. The RTOG study 0129 revealed the effects of HPV status on survival outcomes in a large cohort of 323 patients with advanced OPSCC who were treated with chemoradiotherapy (1). This study found that tobacco use canceled out the advantage of improved survival associated with HPV positivity. In the present study, the patients who were p16-positive and p53-positive OPSCCs (double positive) showed poorer prognoses than those who were p16 positive and p53 negative. The reason why double-positive patients had a poorer prognosis than p16-negative p53-positive patients remains unclear, but may have been due to the relatively small number of cases (only four cases). p16-negative and p53-negative (double-negative) patients also showed the poorest prognoses. The reason for this is not clear, but might be because of other carcinogenic factors stronger than HPV or mutated p53. Another possible reason is the limitation of the sensitivity of p53 IHC for detecting the p53 mutation. Nylander et al. (16) reported that HNSCCs with large p53 mutations, such as deletions causing frame shifts or stop codons, which are reported to cover 12% of OPSCC cases with p53 mutations, produced tumors that were negative for p53 by IHC (36) .
Further studies with large cohorts may help to clarify the relevance of double-positive and double-negative results.
In this study, separation of patients into p16-positive and p53-negative and others was a practical approach. The patients who were p16-positive and p53-negative had better prognoses in terms of OS and DSS than those who were p16-positive alone. Moreover, the combination of p16 positive and p53 negative was a better predictive factor than UICC stage or main treatment strategy. The HR for OS in p16-negative or p53-positive OPSCCs was 20.8 and that for DSS was 12. Significant P values are indicated in italic type.
238
P16 and p53 expression in oropharyngeal carcinomas classification they made was shown to be more predictive only for recurrent-free survival than Ang's original algorithm but not for OS or DSS (37). Molecular subtyping is already common in some malignancies such as breast cancers (38 -40) , and shows great potential for furthering our understanding of OPSCCs. This report may help to generate study models with larger cohorts for improving treatment based on the classification of different molecular subtypes.
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